Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
Status:
Terminated
Trial end date:
2013-09-17
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Giving more than
one drug (combination chemotherapy) together with cetuximab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well chemotherapy given together with cetuximab
works in treating patients undergoing surgery to remove peritoneal carcinomatosis from
colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Institut Bergonié
Collaborators:
Assistance Publique - Hôpitaux de Paris Centre Alexis Vautrin, Nancy Centre Leon Berard Clinique Francheville, Périgueux Hôpital Haut-Lévêque Institut Cancerologie de l'Ouest